Drug intelligence / Profile preview

carboplatin + Iscador + pemetrexed

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of two chemotherapy drugs (carboplatin and pemetrexed) plus Iscador, a mistletoe preparation used in complementary medicine. This combination has been studied in clinical trials for advanced non-small cell lung cancer to evaluate whether adding Iscador to standard chemotherapy could reduce side effects and improve quality of life.

Targets

DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)DNA

Beyond the preview

Go deeper on carboplatin + Iscador + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + Iscador + pemetrexed.

Explore the full profile